Illumina Inc, a gene-mapping company facing a $5.7 billion hostile takeover bid by Swiss drugmaker Roche Holding AG, was sued by Columbia University on Monday for allegedly infringing five patents related to DNA sequencing, Reuters reports. According to the complaint filed in the U.S. District Court in Wilmington, Delaware, Illumina commercialized its so-called next-generation sequencing (NGS) products despite knowing about the patents, obtained between 2009 and 2012 and assigned to Columbia. The university said its patents cover NGS technologies that allow rapid and precise DNA sequencing, which are particularly important in using individuals’ genomic DNA sequence information as a basis for providing health care…
…Read MorePodcast Series: Innovations in Education
Explore the full series of eCampus News podcasts hosted by Kevin Hogan—created to keep you on the cutting edge of innovations in education.